This week in aesthetics, a study examines energy device plume, the U.S. International Trade Commission upholds a 21-month ban on Evolus’ Jeuveau, and more.
This week in aesthetics, a study compares plume in energy devices, Revance announces phase 2 DAXI results, Hydrafacial announces a merger agreement with Vesper Healthcare, the U.S. International Trade Commission upholds a 21-month ban on Evolus’ Jeuveau, ASDS releases guidance for COVID-19 vaccine side effects on filler patients, and we highlight recent FDA approval and clearances, notable partnerships and injectable insights.
InMode recently announced study results comparing fractional RF vs. Er:YAG plume for transmission risk of COVID-19.
Revance Therapeutics announces positive phase 2 DAXI results and provides an update on expected FDA Approval.
FDA approvals in 2020 included Galderma’s Restylane Kysse, Endo Aesthetics QWO for cellulite, and more.
Hydrafacial and Vesper Healthcare recently announced they have entered into a definitive merger agreement expected to close in the first half of 2021.
Notable partnerships in aesthetic medicine include that of Candela and Jabil, Revance and HintMD, among others.
The U.S. International Trade Commission recently announced it will uphold the ban on Jeuveau, changing its original sentence from 10 years to 21 months.
In 2020, injectables saw improvements in consultations, combination therapy, and more.
ASDS releases guidance on reported cases of adverse events related to the Moderna COVID-19 vaccine and dermal filler patients.